For more information about STAR.

, for more information about STAR, including links to media materials and a fact sheet Visit NCI STAR homepage at below or NSABP websites and foundation. Used for tools to calculate a woman’s risk of developing breast cancer, visit cancer.gov / or breast cancer prevention bcrisktool.

In addition, women who were prospectively randomized to raloxifene daily, and take an average of four years followed, had 36 % fewer uterine cancers and 29 % fewer blood clots than the women who were assigned to take tamoxifen. Uterine cancer, particularly endometrial cancers are a rare but serious side effect of tamoxifen. Both tamoxifen and raloxifene are known to increase a woman’s risk of blood clots. In National Surgical Adjuvant Breast and Bowel Project , a network of cancer research professionals coordinated the study by the National Cancer Institute , part of the National Institutes of Health is promoted. STAR enrolled 19,747 postmenopausal women who were at increased risk for the disease.####Hutson received her B. From the University of California San Diego and graduated on the University of Washington. She did her Postdoc in neuroscience and anatomy at University of Utah.

Other entries from category "gynecology":

Tag Cloud